AP82 Stock Chart & Stats
€65970.00
€0.00(0.00%)
At close: 4:00 PM EDT
€65970.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€65,970.00 - €65,970.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.79M
Enterprise Value-€276.14K
Total Cash (Recent Filing)€9.80M
Total Debt (Recent Filing)€4.21M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Nov 05, 2026EPS Estimate
-3.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-211.18
Shares Outstanding1,810,215
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.74Price Target Upside-99.97% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-16.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline PotentialThe reported mipletamig responses in a difficult TP53-mutant AML subgroup indicate meaningful clinical potential and differentiation in an area of high unmet need. If confirmed in the ongoing study, this asset could strengthen Aptevo’s pipeline, regulatory prospects, and partnering position over the next several quarters.
Solid-tumor Platform ExpansionA reusable Nectin-4 x PD-L1 backbone broadens Aptevo’s opportunity beyond a single candidate by supporting radiopharmaceutical, T-cell engager, and immune-based applications. The patent filing may strengthen intellectual property protection and create a platform for multiple assets and future partnerships.
Trispecific Program AdvancementAdvancing APVO451 toward IND-enabling studies demonstrates continued execution on the company’s next-generation trispecific strategy. Efforts to optimize reliable, scalable manufacturing could reduce a material development hurdle, support future clinical progression, and improve the platform’s strategic attractiveness.
Bears Say
Persistent Pre-revenue LossesAptevo has not yet generated reported revenue while sustaining large recurring losses, leaving its cost base unsupported by commercial activity. This weak earnings foundation limits internal funding capacity and makes financial improvement dependent on successful development, regulatory progress, and eventual product commercialization.
Substantial Cash BurnPersistent operating and free-cash-flow outflows indicate that Aptevo consumes significant capital to maintain its development programs. The scale of burn relative to its pre-revenue status increases dependence on external financing and can constrain the company’s ability to sustain or expand its pipeline without additional capital.
Equity Dilution And Fragile Capital BaseApproval for equity issuance exceeding 20% of outstanding shares, together with the company’s reduced equity base, highlights reliance on equity markets to support operations. Further share issuance or warrant exercises could dilute existing holders and reflects limited financial flexibility while losses and cash needs remain high.
Aptevo Therapeutics News
AP82 FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was €65970.00 and its highest was €65970.00 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is €2.79M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 20 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Aug 14, 2026. The company reported -€4.735 earnings per share for the quarter, beating the consensus estimate of -€5.363 by €0.629.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Overvalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -3.31.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,810,215 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -€4.735 in its last earnings report, beating expectations of -€5.363. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:AP82
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
AP82 Stock 12 Month Forecast
Average Price Target
€18.74
▼(-99.97% Downside)